# A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV (RIFT-HPV)

> **NCT05334706** · PHASE4 · RECRUITING · sponsor: **Miquel Angel Pavon Ribas** · enrollment: 69 (estimated)

## Conditions studied

- Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III)
- Human Papillomavirus (HPV) Infections
- High-risk HPV
- HPV-16/ 18

## Interventions

- **BIOLOGICAL:** Nonavalent HPV vaccine (9vHPV/Gardasil-9™).

## Key facts

- **NCT ID:** NCT05334706
- **Lead sponsor:** Miquel Angel Pavon Ribas
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-13
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 69 (ESTIMATED)
- **Last updated:** 2026-02-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05334706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05334706, "A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV (RIFT-HPV)". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05334706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*